Atherosclerosis 1996-07-01

Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.

G Turpin, E Bruckert

Index: Atherosclerosis 124 Suppl , S83-7, (1996)

Full Text: HTML

Abstract

Ciprofibrate is an effective treatment for three main types of atherogenic hyperlipoproteinaemia: type IIa hypercholesterolaemia, type IIb combined hyperlipidaemia, and type IV hypertriglyceridaemia. In type IIa hypercholesterolaemia, administration of 100 mg/day of ciprofibrate, to approximately 3000 patients, decreased total cholesterol (TC), triglycerides, apolipoprotein B (apo B) and low-density lipoprotein (LDL) cholesterol. Levels of apolipoproteins in high-density lipoprotein (HDL) cholesterol and apolipoprotein AI (apo A-I) were increased. Administration of the same dose of ciprofibrate, to approximately 3500 patients with type IIb combined hyperlipidaemia, had a marked cholesterol- and triglyceride-lowering effect, in addition to producing a decrease in LDL cholesterol and apo B, and an increase in apo A-I. TC levels were also decreased in type IV hypertriglyceridaemia following administration of 100 mg/day of ciprofibrate to 800 patients. The decrease in TC levels was attributable to a decrease in triglyceride levels and an increase in HDL cholesterol levels. The pharmacokinetics, mechanism of action and safety of ciprofibrate treatment are also discussed.

Related Compounds

  • Ciprofibrate

Related Articles:

Transcriptional Regulation of Cytosolic Sulfotransferase 1C2 by Intermediates of the Cholesterol Biosynthetic Pathway in Primary Cultured Rat Hepatocytes.

2015-12-01

[J. Pharmacol. Exp. Ther. 355 , 429-41, (2015)]

Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

2009-01-01

[Lipids Health Dis. 8 , 50, (2009)]

Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.

2008-01-01

[Arzneimittelforschung 58(5) , 225-41, (2008)]

Differential regulation of peroxisome proliferator-activated receptor (PPAR)-alpha1 and truncated PPARalpha2 as an adaptive response to fasting in the control of hepatic peroxisomal fatty acid beta-oxidation in the hibernating mammal.

2009-03-01

[Endocrinology 150(3) , 1192-201, (2009)]

Species-specific kinetics and zonation of hepatic DNA synthesis induced by ligands of PPARalpha.

2008-07-01

[Toxicol. Sci. 104(1) , 74-85, (2008)]

More Articles...